The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis

Cancer Research

Volumn 62, Issue 17, 2002, Pages 5089-5095

  Welsh, Sarah J ^a   Bellamy, William T ^a   Briehl, Margaret M ^a   Powis, Garth ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; LUCIFERASE; NITRIC OXIDE SYNTHASE; THIOREDOXIN; THIOREDOXIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CELL LINE; CELL STRAIN HT29; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TRANSACTIVATION; TUMOR VASCULARIZATION;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BREAST NEOPLASMS; CELL HYPOXIA; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOKINES; LYMPHOMA; MEMBRANE PROTEINS; MICE; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; THIOREDOXIN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036735392     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. HIF-1:mediator of physiological and pathophysiological responses to hypoxia
2. Angiogenesis: How a tumor adapts to hypoxia
3. 2 tension
4. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression
5. Oxygen and the hypoxia-inducible factor-1
6. Overexpression of hypoxiainducible factor 1α in common human cancers and metastases
7. Relation of hypoxia-inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic molecular profile of tumors and survival
8. Expression of hypoxia-inducible factor-1α in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis
9. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy
10. Hypoxia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy
11. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer
12. Levels of hypoxia-inducible factor 1α during breast carcinogenesis
13. Expression of hypoxia-inducible factor la in brain tumors: Association with angiogenesis, invasion, and progression
14. Hypoxia-inducible factor la (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: Its stabilization by hypoxia depends upon redox-induced changes
15. 2-dependent degradation domain via the ubiquitin-proteasome pathway
16. 2, and the 3 PHDs: How animal cells signal hypoxia to the nucleus
17. Stabilization of wild-type p53 by hypoxia-inducible factor 1α
18. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
19. Phosphatidylinositol 3-kinase signaling controls the levels of hypoxia-inducible factor 1
20. Loss of PTEN facilitates HIF-1-mediated gene expression
21. Regulation of the hypoxia-inducible factor-1α by the ubiquitin-proteasome pathway
22. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch
23. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its a subunit
24. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression
25. Signal transduction in hypoxic cells: Inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor 1α
26. Molecular mechanisms of transcription activation by HLF and HIF 1α in response to hypoxia: Their stabilization and redox signal-induced interaction with CBP/p300
27. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α
28. Hypoxia-modulated gene expression: Angiogenesis, metastasis, and therapeutic exploitation
29. Activation of the HIF pathway in cancer
30. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
31. Hypoxic cervical cancers with low apoptotic index are highly aggressive
32. Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix
33. Thioredoxin reductase
34. The role of the redox protein thioredoxin in cell growth and cancer
35. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1
36. Phage display identifies thioredoxin and superoxide dismutase as novel protein kinase C-interacting proteins: Thioredoxin inhibits protein kinase C-mediated phosphorylation of histones
37. Oxidoreductive regulation of nuclear factor κB: Involvement of a cellular reducing catalyst thioredoxin
38. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function
39. Thioredoxin-dependent redox regulation of p53-mediated p21 activation
40. Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of breast cancer cells
41. A redox-inactive thioredoxin reduces growth and enhances apoptosis in WEHI7.2 cells
42. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): Thioredoxin mRNA is elevated in some human tumors
43. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia
44. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer
45. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival
46. Increased expression of thioredoxin in human primary and metastatic colon cancer
47. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo
48. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer
49. Expression of vascular endothelial growth factor (VEGF) and its receptors in hematopoietic malignancies
50. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers
51. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
52. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin
53. AP endonucleases and the many functions of Ref-I
54. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1
55. The contribution of proangiogenic factors to the progression of malignant disease: Role of vascular endothelial growth factor and its receptors
56. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
57. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis
58. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
59. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
60. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer
61. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor-1
62. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-β1-activated p38 signaling pathway enhances endothelial cell migration
63. Nuclear-targeted thioredoxin transforms NIH 3T3 cells
64. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism